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license (http://creativeas an add-on to pre-existing treatment with acetylcholinesterase inhibitors. The objective of this study
was to evaluate the efficacy and safety of a combined memantine and galantamine-CR de novo
regimen compared with galantamine-CR only treatment in never treated patients with mild-to-
moderate Alzheimer’s disease (AD).
Methods: Antidementia drug–na€ıve participants (n 5 232) with probable, mild-to-moderate AD,
and mini-mental state examination scores between 15 and 26 (inclusive) were randomized to receive
either 20 mg/day memantine plus 24 mg/day galantamine-CR or 24 mg/day galantamine-CR plus
placebo in a 52-week, prospective, double-blind, controlled trial. The primary outcome measurement
was the change on the Alzheimer’s disease assessment scale-cognition score. Secondary measures
comprised the Alzheimer’s Disease Cooperative Study-activities of daily living inventory and the
clinical dementia rating.
Results: At the end of the trial, there were no statistically significant differences between the
galantamine-CR/memantine combination and galantamine-CR only group in primary and secondary
outcome measurements. The incidence and the severity of adverse events were similar between the
groups.
Discussion: In this trial, memantine in combination with galantamine-CR did not show an advantage
with respect to cognition, function, and behavior in previously never treated patients with mild-to-
moderate AD. There were no significant differences in tolerability and safety between the groups.thor. Tel.:149-30450517628; Fax:149-30450517942.
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Although there is a great hope that disease-modifying
therapies can be developed in the near future, until today,
acetylcholinesterase inhibitors (AChEIs), such as galant-
amine, rivastigmine, donepezil, and the N-methyl-D-aspar-
tate (NMDA) receptor antagonist memantine, remain the
only approved drugs for the treatment of Alzheimer’s dis-
ease (AD). The rationale to combine the different modes
of action, namely an AChEI and an NMDA receptor antag-
onist, to increase the therapeutic benefit appears promising.
However, until now, there is an ongoing debate about the
benefit of memantine as an add-on strategy to AChEI treat-
ment in AD [1,2].
Studies supporting efficacy and safety of combination
treatment in moderate (mini-mental state examination
[MMSE] 5 10–20), and specially, severe AD (MMSE
,10), have been reported [3,4]. In contrast, findings in
mild-to-moderate AD revealed that the combination strategy
does not show consistent benefits. A double-blind trial with
different AChEIs [5], an open-label trial with rivastigmine
[6] and a cohort-observational study with donepezil [7],
did not report significant cognitive benefits of combination
treatment with memantine. Only an open-label trial with ri-
vastigmine found greater symptomatic improvements with
add-on memantine [8]. So far, one might speculate that the
efficacy of this treatment throughout AD stages is inversely
proportional to the scores on the MMSE: the lower the score,
the more effective the add-on strategy appears to be. In all
these studies, memantine was subsequently added to an ex-
isting AChEI monotreatment.
In summary, studies to date have primarily focused on
the possible usefulness of an add-on treatment. However,
the benefit of a de novo combination treatment in previously
never treated mild-to-moderate AD (MMSE: 15–26) pa-
tients had not yet been tested in a randomized, double-
blind, controlled trial. Based on these considerations, the
first objective of the present study was to assess the long-
term efficacy, safety, and tolerability of galantamine-
continuous-release (CR) and concomitant memantine in
treating antidementia drug–na€ıve patients with mild-to-
moderate AD for a longer period of time (52 weeks).
Furthermore, we explored whether memantine add-on treat-
ment, as compared with galantamine-CR only, had an effect
on disease progression.2. Methods
2.1. Participants
A total of 232 community-dwelling participants were re-
cruited at 12 centers in Germany. The patients met the
following inclusion criteria: age 50 years; diagnosis of
probable AD according to the criteria of the National Insti-
tute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) and the German Demen-
tia Competence Network [9]; results of an MRI or CT
within the past 12 months consistent with a diagnosis of
probable AD; MMSE score5 15–26 at screening and base-
line; absence of previous treatments with AChEIs or mem-
antine; vision and hearing sufficient to permit compliance
with assessments; and an informed and reliable caregiver
to accompany the participant to all study visits and to super-
vise the administration of the study drug. Exclusion criteria
included presence of clinically significant medical, psychi-
atric, neurodegenerative, or intracerebral diseases. Vitamin
B12 and folate deficiency as well as active pulmonary,
gastrointestinal, renal, hepatic, endocrine, or cardiovascu-
lar disease were explicitly excluded. This study was
approved by the ethics committee of the Charite Medical
School. Written informed consent was provided by the pa-
tient’s caregiver and either the patient (if possible) or a le-
gally acceptable representative (if not the caregiver)
before initiation of study-specific procedures.2.2. Trial design
A 52-week, prospective, randomized, double-blind,
controlled trial was conducted. At the baseline visit, partic-
ipants were randomly assigned in a 1:1 ratio to one of two
treatment groups: (1) galantamine only: galantamine-CR
24 mg/day with dose-titration over 12 weeks (mainte-
nance phase starting at week 9) and placebo capsules; (2)
galantamine/memantine combination: a combination of
galantamine-CR 24 mg/day plus memantine 10 mg b.i.d.
with a dose-titration phase over 16 weeks (12 weeks for
galantamine-CR [maintenance phase starting at week 9],
additional 4 weeks for memantine). Participants received
one capsule (galantamine-CR) and two pills (memantine
or placebo) each day. The galantamine-CR group received
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equal with regard to shape, color, and size. The randomiza-
tion was performed in blocks with a block length of six. The
participants assigned to the galantamine-CR only group
received over 4 weeks 8 mg/day galantamine-CR, followed
by 4 weeks of 16 mg/day and 24 mg/day starting in week 9
until the end of the trial. The patients assigned to the
galantamine-CR/memantine combination group received a
memantine titration over 4 weeks in steps of 5 mg/day up
to 20 mg/day (10 mg b.i.d.). Half of this group received
galantamine-CR first, the other half receivedmemantine first
to allow for differential qualitative evaluation of tolerability
of a combination treatment. Any change in dosage or discon-
tinuation of galantamine-CR was recorded, and the patients
were discontinued from the study if the inclusion criterion
of concomitant memantine dosing was no longer met. All
patients on memantine were required to receive the target
dose of 20 mg/day at the beginning of weeks 4 or 16
(depending on the group type). Patients, who did not tolerate
the target dose, were excluded. Compliance and adherence
with the study medication were monitored by an inventory
of individually returned blister packs and routine assessment
of concomitant medication use. The overall education, expe-
rience, and training of study personnel were adequate to
conduct clinical trials according to good clinical practice,
and the researchers were qualified and trained in the treat-
ment of AD. The primary outcome measurement was the
change from baseline on the Alzheimer’s Disease Assess-
ment Scale-cognitive subscale (ADAS-cog) score. Second-
ary measures comprised the Alzheimer Disease Cooperative
Study-activities of daily living scale (ADCS-ADL) and clin-
ical dementia rating (CDR). The outcome measurements
were reassessed in weeks 16, 26, and 52. No individual
participant randomization code had to be revealed during
the trial.
2.3. Sample size
The number of patients to be enrolled into this trial was
calculated under the following assumptions: (1) The num-
ber of patients allocated to the individual arms of the trial
should be balanced; (2) the maximum tolerable risk for an
error of the second kind is 15%, corresponding to a power
of at least 85%; (3) for both groups, the underlying distribu-
tions are normal (4); the difference between the means of
the two normal distributions under comparison equals
d5 40% of the square root of the common population vari-
ance. Based on these assumptions, the usual procedure for
the exact computation of the sample size required in the
one-sided two-sample t test with a5 0.05 showed the min-
imum sample size required under the above conditions to be
n 5 70 per group. To be on the safe side, we allowed for a
drop-out rate of up to 40%. Accordingly, the total number of
AD patients to be recruited to this trial was fixed at
2! 120 5 240.2.4. Statistical analysis
The analyses were based on the intention-to-treat (ITT)
population (patients who were randomized to receive
either galantamine-only or memantine add-on treatment,
and who completed at least one baseline and one post-
baseline ADAS-cog assessment) and per-protocol (PP)
set (patients who completed the 52 weeks as planned
and had measurements for all efficacy variables with no
major protocol violations). The statistical analyses were
done using SPSS software (version 21) for Windows
and were conducted at the two-sided, 5% significance
level. Results were expressed as mean 6 standard error.
The outcome differences in ADAS-cog, ADCS-ADL,
and CDR scores were compared by means of an unpaired
Student t test analysis. The baseline and different time-
point measurements were compared using the paired Stu-
dent t test. Differences in frequencies in adverse events
(AEs) were tested using Pearson’s c2 test.2.5. Sponsoring
This study was sponsored by the German Federal Minis-
try of Education and Research (Bundesministerium f€ur Bil-
dung und Forschung). Galantamine-CR and memantine
were provided by Janssen-Cilag and Merz.3. Results
3.1. Study population
The study assessed 232 patients from the German De-
mentia Competence Network (DCN) cohort [9] for eligi-
bility, 6 of whom were found not suitable based on the
inclusion and exclusion criteria (Fig. 1). When the last pa-
tients were recruited, it could be foreseen that the overall
drop-out rate in the study will end up far below calcula-
tion; therefore, recruitment was already halted closely
before 240 patients were recruited. A total of 226 partic-
ipants were randomly assigned (1:1) to receive either
galantamine-CR only treatment (n 5 114) or galantamine-
CR/memantine combination treatment (n 5 112), with 87
(76.31%) and 82 (73.21%) participants completing the
trial, respectively. Thereby, the overall drop-out rate of
27.15% was substantially lower than calculated. The ITT
population comprised 190 patients (96 galantamine-CR
only; 94 galantamine-CR/memantine combination). The
PP population comprised 169 patients (87 galantamine-
CR only; 82 galantamine-CR/memantine combination).
AEs were the most frequent reason for discontinuation in
both groups. The treatment groups were well matched for
demographic and clinical characteristics at baseline
(Table 1). A small but only statistically significant differ-
ence was noticed in the MMSE scores: galantamine-CR
only, 22.6 6 3.1; galantamine-CR/memantine combination,
Fig. 2. Primary outcome measure Alzheimer’s Disease Assessment Scale
(ADAS-cog). Sample size at week 16 (Combi/GAL-only): 184 (91/93); at
week 26: 175 (90/85) and at week 52: 170 (86/84). Data are presented as
mean and standard deviation. Abbreviations: COMBI group, galantamine-
CR/memantine combination; GAL-only group, galantamine-CR; LOCF,
last observation carried forward.
Fig. 1. Study flow. Abbreviations: GAL-only, galantamine-CR; PP, per pro-
tocol; ITT, intention to treat.
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mild-to-moderate AD.
3.1.1. Primary outcome measure
Both ITT and PP analyses were performed to assess effi-
cacy. Analyses using the last observation carried forwardTable 1
Demographic and clinical characteristics of both study groups at baseline
Characteristics Galantamine-CR
Galantamine-CR/
memantine combination
n 114 112
Age 72.6 (7.8) 72.1 (8.5)
Female % 68.4 58.9
MMSE 22.6 (3.1) 21.7 (3.2)*
ADAS-cog 18.9 (6.6) 20.2 (7.0)
ADCS-ADL 62.1 (12.9) 62.1 (10.5)
NPI 7.9 (9.7) 5.7 (6.7)
CDR (SOB) 4.8 (1.4) 5 (1.5)
MADRS 6.8 (4.7) 7.2 (5.4)
Abbreviations: MMSE, mini-mental state examination; ADAS-cog, Alz-
heimer’s disease assessment scale; ADCS-ADL, Alzheimer’s Disease
Cooperative Study ADL; NPI, neuropsychiatric inventory; CDR-SOB, clin-
ical dementia rating scale–sum of boxes; MADRS, Montgomery-Asberg
depression rating scale.
NOTE. *P , .05.(LOCF) approach showed no statistically significant differ-
ences between the treatment groups in the ADAS-cog dur-
ing any visit throughout the trial (at the end point:
P 5 .831). At baseline, the galantamine-CR only and the
galantamine-CR/memantine combination groups showed
mean values of 18.9 6 6.6 and 20.2 6 7, respectively
(P 5 .165). In week 16, both groups—especially the
galantamine-CR/memantine combination group—showed
a statistically insignificant improvement in the primary
outcome (Fig. 2). From week 16 to 52, the mean values of
both groups approximated each other over time and
increased significantly from baseline to the end point
(P 5 .025 and P 5 .038, respectively). Similarly, analyses
using the PP approach showed no statistically significant
differences between the treatment groups at the end of the
treatment (P 5 .781) and significant differences between
the baseline and week 52 (P 5 .015 and P 5 .023, respec-
tively).
3.1.2. Secondary outcome measurements
The secondary outcomes included the ADCS-ADL and
the CDR and the neuropsychological inventory (NPI). At
baseline, there were no statistically significant differences be-
tween the groups in mean values (ADCS-ADL: 62.1 6 12.9
and 62.1 6 10.5, P 5 .980; CDR: 4.8 6 1.4 and 5 6 1.5,
P 5 .297; NPI: 7.9 6 9.7 and 5.7 6 6.7, P 5 .067). The
mean ADCS-ADL and CDR values of both treatment groups
remained below baseline throughout the trial (Figs. 3 and 4).
LOCF analyses showed that at the end point the scores of both
tests worsened significantly compared with baseline in the
galantamine-CR only group (P , .001) and in the
galantamine-CR/memantine combination group (P , .001)
and no significant differences were detected between the
treatment groups (ADCS-ADL: P 5 .719; CDR: P 5 .921).
The mean NPI score had slightly improved, but not
Fig. 3. Secondary outcome measure Alzheimer’s Disease Cooperative
Study-activities of daily living scale (ADCS-ADL). Sample size at week
16 (Combi/GAL-only): 151 (77/74); at week 26: 149 (72/77) and at week
52: 136 (66/70). Data are presented as mean and standard deviation. Abbre-
viations: COMBI group, galantamine-CR/memantine combination; GAL-
only group, galantamine-CR; LOCF, last observation carried forward.
Table 2
Summary of adverse events
Patients at risk for AE/unique
patients with AE
Galantamine-CR
Galantamine-CR/
memantine
combination
n 5 114 n 5 80 n 5 112 n 5 89
Total (serious) adverse events 178 (19) % 189 (20) %
Nervous system events 42 (3) 23.6 42 (4) 22.2
Gastrointestinal system events 37 (3) 20.7 36 (3) 19.0
Cardiac and vascular events 22 (4) 12.3 27 (4) 14.3
Fall 14 (3) 7.9 18 (4) 9.5
Otolaryngologic events 7 4.0 10 (1) 5.3
Skin events 5 2.8 13 6.9
Endocrine events 1 0.5 3 1.6
Urinary system events 8 (2) 4.5 7 3.7
Metabolic-nutritional events 3 1.7 2 1.0
Respiratory, thoracic, and
mediastinal events
9 (1) 5.0 8 (3) 4.2
Other 30 (3) 16.8 23 (1) 12.1
Abbreviation: AE, adverse events.
NOTE. The number of serious adverse events is indicated in parentheses.
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at the end of treatment (P 5 .064). At the end point, there
were no significant differences in both groups compared
with baseline (galantamine-CR only: P , .344;
galantamine-CR/memantine combination: P , .078).
Once again, the analysis of results of the PP approach fol-
lowed the same trend as the ITT approach. In week 52, the
scores of the ADCS-ADL and CDR worsened significantly
compared with the baseline in the galantamine-CR only
group (P , .001 and P , .001, respectively) and in the
galantamine-CR/memantine group (P , .001 and P , .001,
respectively) and no significant differences were detected be-
tween the treatment groups (ADCS-ADL: P 5 .149; CDR:
P5 .802). The mean NPI score did not differ between groupsFig. 4. Secondary outcome measure clinical dementia rating scale–sum of
boxes. Sample size at week 16 (Combi/GAL-only): 188 (94/94); at week 26:
177 (87/90); at week 39: 177 (86/91) and at week 52: 172 (84/88). Data are
presented as mean and standard deviation. Abbreviations: COMBI group,
galantamine-CR/memantine combination; GAL-only group, galantamine-
CR; LOCF, last observation carried forward.in week 52 (P5 .106). At the end of the treatment, there were
no significant differences in both groups compared with the
baseline (galantamine-CR only: P , .390; galantamine-CR/
memantine: P , .138).3.2. Safety and tolerability
A summary of AEs is listed in Table 2. The most common
AEs involved the nervous system (galantamine-CR only: 42
[23.6%], galantamine-CR/memantine combination: 42
[22.2%]). A total of 80 galantamine-CR only treated patients
(70.17%) and 89 galantamine-CR/memantine combination
treated patients (79.4%) reported AEs, with both groups
showing, in general, a similar AE profile (P5 .108). Serious
AEs were experienced by 15 galantamine-CR only treated
(13.1%) and 15 galantamine-CR/memantine combination
treated patients (13.3%). One patient of 226 (0.44%) died
during the trial in the galantamine-CR/memantine combina-
tion group. This death was judged to be not related or even
remotely related to treatment in thememantine-treated group.4. Discussion
This is the first prospective, randomized, double-blind,
controlled trial examining the efficacy of a combination of
an AChEI (galantamine-CR) and the NMDA receptor
antagonist (memantine) in antidementia-na€ıve patients
with mild-to-moderate AD. A treatment of 52 weeks
with 24 mg/day galantamine-CR in combination with
20 mg/day memantine had no significant benefit over
galantamine-CR alone on cognitive function, activities
of daily living, and disease progression.
Benefits of a memantine monotreatment in patients with
mild AD using standard cognitive and functional measure-
ments have not been consistently reported [10–13].
Similarly, most of the recent studies found that a
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istration resulted in no cognitive enhancement in mild-to-
moderate AD patients when compared with AChEIs alone
[5–7]. Likewise, a double-blind, placebo-controlled trial re-
vealed that memantine did not show an advantage over pla-
cebo, based on protocol-specified primary (ADAS-cog and
Clinician’s Interview-Based Impression of Change with
caregiver input [CIBIC-plus]) or secondary outcomes
(ADCS-ADL, NPI, MMSE, the Resource Utilization in De-
mentia (RUD)) in patients with mild-to-moderate AD on
stable AChEI medication [5]. Our study supports these find-
ings and extends them to antidementia-na€ıve, mild-to-
moderately severe AD patients and a much longer trial
period (24 vs. 52 weeks, respectively).
To date, there is only one published study suggesting a
cognitive benefit of a combination strategy in mild-to-
moderate AD: Riepe et al. [8] reported in a small open-label
study that a combination of memantine with rivastigmine re-
sulted in a statistically significant improvement in both the
ADAS-cog total score and the MMSE score in mild-to-
moderate AD. However, it is noteworthy that the change in
ADAS-cog score (1.7 points) was less than the 4-point change
considered clinically relevant by the US Food and Drug
Administration [14].
On the other hand, two randomized, double-blind, pla-
cebo-controlled trials in moderate-to-severe AD (MMSE
scores from 3–5 to 13–17) supported the notion that mem-
antine, when added to prior, stable AChEIs may have sig-
nificant benefits in reducing decline in cognition,
functioning, and global status [3,4]. However, other
studies disagree. In a double-blind, placebo-controlled trial
(n 5 295; MMSE: 5–13), Howard et al. [15] found that
AChEI treatment was discontinued before the efficacy of
an AChEI and memantine did not differ significantly in
the presence or absence of the other; furthermore, there
were no significant benefits of the combination of AChEI
and memantine over AChEI alone.
In conclusion, a combination strategy does not seem to
be cognitively or functional advantageous in mild-to-
moderately affected AD patients who had never before
received antidementia drugs. More specifically, the slopes
of cognitive decline were similar between the two groups.
This strategy may be considered safe and well tolerated in
this kind of patients.
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1. Systematic review: Studies supporting efficacy and
safety of memantine as an add-on strategy to AChEI
treatment in moderate-to-severe AD, have been re-
ported. However, findings in mild-to-moderate AD
revealed no consistent benefits.
To our knowledge, this is the first randomized
controlled trial (RCT) of a large number of antidemen-
tia-na€ıve, mild-to-moderately severe Alzheimer’s pa-
tients receiving either a combination treatment of
memantine and galantamine (AD COMBI) or gal-
antamine (AD GAL) alone for 52 weeks.
2. Interpretation: In this RCT, we did not find any clin-
ically relevant or statistically significant benefits of
the combination treatment. Furthermore, the slopes
of cognitive, functional, and global decline were
similar between the AD-COMBI and the AD-GAL
groups. Interestingly, a significant global decline
was noted in both groups starting at week 26. Thus,
we conclude that in previously antidementia na€ıve
patients with Alzheimer’s disease, combining the N-
methyl-D-aspartate modulator memantine with the
acetylcholine-inhibitor galantamine results in no
improvement over galantamine alone.
3. Future directions: We feel that our study would be of
great interest to the reader of your journal, given the
need for an effective “palliative” treatment for Alz-
heimer’s disease, until, hopefully in the not so distant
future, a disease-modifying strategy is available.
Also, this is one of the very few trials where patients
were treatedwith an antidementia drug combination for
a duration of as long as 52 weeks.References
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